BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, Tiro JA, Yopp AC, Parikh ND, Marrero JA, Singal AG. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology 2017;65:875-84. [PMID: 27531684 DOI: 10.1002/hep.28770] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Costentin CE, Sogni P, Falissard B, Barbare JC, Bendersky N, Farges O, Goutte N. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C. Dig Dis Sci 2020;65:301-11. [PMID: 31346950 DOI: 10.1007/s10620-019-05724-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dai J, Zhao J, Du Y, Zhuang L, McNeil EB, Chongsuvivatwong V. Adherence to Hepatocellular Carcinoma Surveillance and Perceived Barriers Among High-Risk Chronic Liver Disease Patients in Yunnan, China. Cancer Manag Res 2020;12:6209-20. [PMID: 32884337 DOI: 10.2147/CMAR.S259195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhao C, Jin M, Le RH, Le MH, Chen VL, Jin M, Wong GL, Wong VW, Lim YS, Chuang WL, Yu ML, Nguyen MH. Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. Liver Int. 2018;38:503-514. [PMID: 28834146 DOI: 10.1111/liv.13555] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
4 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
5 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181. [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
7 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
8 Paro A, Dalmacy D, Tslimigras DI, Cloyd J, Ejaz A, Pawlik TM. Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2022. [PMID: 35441305 DOI: 10.1245/s10434-022-11726-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
10 Li C, Lu X, Xiao J, Chan CWH. 'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. J Clin Nurs 2021. [PMID: 34816510 DOI: 10.1111/jocn.16140] [Reference Citation Analysis]
11 Roskilly A, Rowe IA. Surveillance for hepatocellular cancer. Clin Med (Lond). 2018;18:s66-s69. [PMID: 29700096 DOI: 10.7861/clinmedicine.18-2-s66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Dai J, Zhao J, Du Y, Zhuang L, Ma Y, Chongsuvivatwong V. Clinico-Psychosocial Factors Predicting Hepatocellular Carcinoma Related Knowledge Among Patients with Chronic Liver Disease. J Cancer Educ 2020;35:937-45. [PMID: 31090039 DOI: 10.1007/s13187-019-01545-y] [Reference Citation Analysis]
13 Low JTS, Rohde G, Pittordou K, Candy B, Davis S, Marshall A, Stone P. Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health professionals. J Hepatol 2018;69:1260-73. [PMID: 30243996 DOI: 10.1016/j.jhep.2018.08.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
14 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology 2018;155:431-442.e10. [PMID: 29729258 DOI: 10.1053/j.gastro.2018.04.027] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
16 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:577-90. [DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00866-1. [PMID: 34391922 DOI: 10.1016/j.cgh.2021.08.010] [Reference Citation Analysis]
21 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Reference Citation Analysis]
22 Abara WE, Spradling P, Zhong Y, Moorman A, Teshale EH, Rupp L, Gordon SC, Schmidt M, Boscarino JA, Daida YG, Holmberg SD; CHeCS Investigators. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer 2020;51:461-8. [PMID: 31124041 DOI: 10.1007/s12029-019-00255-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Low ES, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World J Gastrointest Oncol 2021; 13(12): 2149-2160 [DOI: 10.4251/wjgo.v13.i12.2149] [Reference Citation Analysis]
24 Marquardt P, Liu PH, Immergluck J, Olivares J, Arroyo A, Rich NE, Parikh ND, Yopp AC, Singal AG. Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatol Commun 2021;5:1481-9. [PMID: 34510836 DOI: 10.1002/hep4.1735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, Yopp AC, Singal AG. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019;17:551-559.e1. [PMID: 29859983 DOI: 10.1016/j.cgh.2018.05.039] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
26 Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, Yopp AC, Parikh ND, Scaglione SJ. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med. 2017;130:1099-1106.e1. [PMID: 28213044 DOI: 10.1016/j.amjmed.2017.01.021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
27 Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology 2021;73:713-25. [PMID: 32383272 DOI: 10.1002/hep.31309] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 55.0] [Reference Citation Analysis]
28 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
29 Wong RJ, Ahmed A; Hepatocellular Carcinoma Research Committee of the Chronic Liver Disease Foundation. Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care: Opportunities to Improve Hepatocellular Carcinoma Outcomes.J Clin Gastroenterol. 2020;54:850-856. [PMID: 33030855 DOI: 10.1097/MCG.0000000000001422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tachi K, Agyei-Nkansah A, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J 2020;36:43. [PMID: 32774619 DOI: 10.11604/pamj.2020.36.43.21085] [Reference Citation Analysis]
31 Hernaez R, El-Serag HB. Hepatocellular carcinoma surveillance: The road ahead. Hepatology 2017;65:771-3. [PMID: 27943335 DOI: 10.1002/hep.28983] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
32 Schauer C, van Rijnsoever M, Gane E. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand. J Viral Hepat 2019;26:1372-6. [PMID: 31323163 DOI: 10.1111/jvh.13179] [Reference Citation Analysis]
33 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
34 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
35 Guss D, Sherigar J, Mohanty SR. Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. Gastroenterology Res 2018;11:333-9. [PMID: 30344803 DOI: 10.14740/gr1074w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Desai N, Rich NE, Jain MK, Blackwell JM, Murphy CC, Perryman P, McBryde J, Quirk L, Clark C, Villarreal D, Waljee AK, Gopal P, Singal AG. Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. Am J Gastroenterol 2021;116:976-83. [PMID: 33337657 DOI: 10.14309/ajg.0000000000001085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Costentin CE, Mourad A, Lahmek P, Causse X, Pariente A, Hagège H, Dobrin AS, Becker C, Marks B, Bader R, Condat B, Héluwaert F, Seitz JF, Lesgourgues B, Denis J, Deuffic-burban S, Rosa I, Decaens T; for the CHANGH Study Group. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study: Delayed Diagnosis of Alcohol-Related HCC. Cancer 2018;124:1964-72. [DOI: 10.1002/cncr.31215] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
39 Sobotka LA, Hinton A, Conteh LF. Insurance status impacts treatment for hepatocellular carcinoma. Ann Hepatol 2019;18:461-5. [PMID: 31040093 DOI: 10.1016/j.aohep.2018.10.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
40 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Guo A, Pomenti S, Wattacheril J. Health Disparities in Screening, Diagnosis, and Treatment of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:353-8. [PMID: 34136141 DOI: 10.1002/cld.1057] [Reference Citation Analysis]
42 Everett BT, Lidofsky SD. Adherence to surveillance endoscopy following hospitalization for index esophageal variceal hemorrhage. World J Gastrointest Surg 2018; 10(4): 40-48 [PMID: 29707105 DOI: 10.4240/wjgs.v10.i4.40] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
43 Wong RJ, Saab S, Konyn P, Sundaram V, Khalili M. Rural-Urban Geographical Disparities in Hepatocellular Carcinoma Incidence Among US Adults, 2004-2017. Am J Gastroenterol 2021;116:401-6. [PMID: 32976121 DOI: 10.14309/ajg.0000000000000948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022;75:541-9. [PMID: 34618932 DOI: 10.1002/hep.32185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
47 Ladhani S, Ohri A, Wong RJ. Disparities in Hepatocellular Carcinoma Surveillance: Dissecting the Roles of Patient, Provider, and Health System Factors. Journal of Clinical Gastroenterology 2020;54:218-26. [DOI: 10.1097/mcg.0000000000001313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
49 Luo P, Liang C, Zhang X, Liu X, Wang Y, Wu M, Feng X, Tu J. Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC. Biosci Rep 2018;38:BSR20171359. [PMID: 29559565 DOI: 10.1042/BSR20171359] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
50 Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer 2020;127:45-55. [PMID: 33103243 DOI: 10.1002/cncr.33211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Mokdad AA, Murphy CC, Pruitt SL, Mansour JC, Marrero JA, Singal AG, Yopp AC. Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma: HCC at Safety Net Hospitals. Cancer 2018;124:743-51. [DOI: 10.1002/cncr.31066] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
52 Choi DT, Kum HC, Park S, Ohsfeldt RL, Shen Y, Parikh ND, Singal AG. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019;17:976-987.e4. [PMID: 30616961 DOI: 10.1016/j.cgh.2018.10.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
53 Nahon P, Ronot M. Repeating Ultrasound for Hepatocellular Carcinoma Detection in Case of Inadequate Liver Visualization: A Matter of Expertise. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00826-0. [PMID: 34358716 DOI: 10.1016/j.cgh.2021.07.044] [Reference Citation Analysis]
54 Singal AG, Reddy S, Radadiya Aka Patel H, Villarreal D, Khan A, Liu Y, Cerda V, Rich NE, Murphy CC, Tiro JA, Kramer JR, Hernaez R. Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01309-4. [PMID: 34902568 DOI: 10.1016/j.cgh.2021.12.014] [Reference Citation Analysis]
55 Chen VL, Singal AG, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver Int 2020;40:947-55. [PMID: 31943689 DOI: 10.1111/liv.14379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
56 Singal AG, Tiro JA, Murphy CC, Marrero JA, McCallister K, Fullington H, Mejias C, Waljee AK, Pechero Bishop W, Santini NO, Halm EA. Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. Hepatology 2019;69:121-30. [PMID: 30070379 DOI: 10.1002/hep.30129] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
57 Ajayi F, Jan J, Singal AG, Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. Curr Hepatol Rep 2020;19:462-9. [PMID: 33828937 DOI: 10.1007/s11901-020-00554-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Luu S, Hsu C, Silberfein EJ. Demographic and Clinicopathologic Factors of Patients With Hepatocellular Carcinoma in a Safety Net Hospital. J Surg Res 2020;256:374-80. [PMID: 32739621 DOI: 10.1016/j.jss.2020.06.046] [Reference Citation Analysis]
59 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
60 Robinson A, Tavakoli H, Cheung R, Liu B, Bhuket T, Wong RJ. Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening. J Clin Gastroenterol 2019;53:65-70. [PMID: 29629906 DOI: 10.1097/MCG.0000000000001024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
61 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
62 Tran SA, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S, Henry L, Nguyen MH. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol 2018;5:e000192. [PMID: 29607053 DOI: 10.1136/bmjgast-2017-000192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
63 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
65 Im S, Jang ES, Lee JH, Lee CS, Kim BH, Chung JW, Kim JW, Jeong SH. Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study. Cancer Res Treat 2019;51:1357-69. [PMID: 30744319 DOI: 10.4143/crt.2018.430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
66 Zhou Y, Zhang W, Ma J, Zhang Z, Yang M, Luo J, Yan Z. The Impact of Socioeconomic Status on Staging, Prognosis in Hepatocellular Carcinoma. IJGM 2022;Volume 15:1459-69. [DOI: 10.2147/ijgm.s353402] [Reference Citation Analysis]
67 Deng H, Shang W, Wang K, Guo K, Liu Y, Tian J, Fang C. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles. J Nanobiotechnology 2022;20:156. [PMID: 35331259 DOI: 10.1186/s12951-022-01378-w] [Reference Citation Analysis]
68 Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017;66:1546-55. [PMID: 28605060 DOI: 10.1002/hep.29315] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
69 Aby ES, Winters AC, Lin J, Bui A, Kawamoto J, Goetz MB, Bhattacharya D, Pisegna JR, May FP, Patel AA, Benhammou JN. A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. Hepatol Commun 2020;4:825-33. [PMID: 32490319 DOI: 10.1002/hep4.1511] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Xing H, Liang L, Li ZL, Zhang H, Yang T. Reliability and validity analyses are essential for questionnaire research. Hepatology 2017;66:1008-9. [PMID: 28558127 DOI: 10.1002/hep.29295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
71 Goldsworthy MA, Rowe IA. Patient understanding of hepatocellular carcinoma surveillance. Hepatology 2017;66:292. [PMID: 28195334 DOI: 10.1002/hep.29103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Mato JM, Elortza F, Lu SC, Brun V, Paradela A, Corrales FJ. Liver cancer-associated changes to the proteome: what deserves clinical focus? Expert Rev Proteomics 2018;15:749-56. [PMID: 30204005 DOI: 10.1080/14789450.2018.1521277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
73 Singal AG, Chen Y, Sridhar S, Mittal V, Fullington H, Shaik M, Waljee AK, Tiro J. Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00217-2. [PMID: 33662594 DOI: 10.1016/j.cgh.2021.02.038] [Reference Citation Analysis]
74 Taylor EJ, Rowe IA. Surveillance for Hepatocellular Carcinoma. In: Cross T, Palmer DH, editors. Liver Cancers. Cham: Springer International Publishing; 2019. pp. 13-21. [DOI: 10.1007/978-3-319-92216-4_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Hernaez R, Kramer JR, Khan A, Phillips J, McCallister K, Chaffin K, Hernandez AP, Fullington H, Ortiz C, Blackwell JM, Loewen A, Liu Y, Tiro JA, Lee SC, Singal AG. Depression and Anxiety Are Common Among Patients With Cirrhosis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31154-X. [PMID: 32835845 DOI: 10.1016/j.cgh.2020.08.045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
76 Simmons OL, Feng Y, Parikh ND, Singal AG. Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2019;17:766-73. [PMID: 30056183 DOI: 10.1016/j.cgh.2018.07.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
77 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
78 Costentin C, Ganne-Carrié N, Rousseau B, Gérolami R, Barbare JC. [Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017]. Bull Cancer 2017;104:752-61. [PMID: 28751065 DOI: 10.1016/j.bulcan.2017.06.008] [Reference Citation Analysis]
79 Jiar N, Slama JL, Ganne-Carrié N. [Screening of hepatocellular carcinoma in patients with uncomplicated cirrhosis in real life: Practices survey of general practionners from three towns of Seine-Saint-Denis (north-east suburb of Paris)]. Bull Cancer 2017;104:618-24. [PMID: 28688744 DOI: 10.1016/j.bulcan.2017.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Mora MI, Molina M, Odriozola L, Elortza F, Mato JM, Sitek B, Zhang P, He F, Latasa MU, Ávila MA, Corrales FJ. Prioritizing Popular Proteins in Liver Cancer: Remodelling One-Carbon Metabolism. J Proteome Res 2017;16:4506-14. [PMID: 28944671 DOI: 10.1021/acs.jproteome.7b00390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
81 Shim JJ, Kim GA, Oh CH, Kim JW, Myung J, Kim BH, Oh IH. Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study. Cancer Med 2020;9:7781-91. [PMID: 32857923 DOI: 10.1002/cam4.3421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Ashhab AA, Rodin H, Powell J, Debes JD. Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant. J Hepatol 2017;67:648-9. [PMID: 28501529 DOI: 10.1016/j.jhep.2017.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
83 Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, Liu Y, Zhang S, Phillips JL, Hernaez R. Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:987-995.e1. [PMID: 32629122 DOI: 10.1016/j.cgh.2020.06.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
84 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
85 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Shaw J, Patidar KR, Reuter B, Hajezifar N, Dharel N, Wade JB, Bajaj JS. Focused Education Increases Hepatocellular Cancer Screening in Patients with Cirrhosis Regardless of Functional Health Literacy. Dig Dis Sci 2021;66:2603-9. [PMID: 32889600 DOI: 10.1007/s10620-020-06583-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31272-6. [PMID: 32927050 DOI: 10.1016/j.cgh.2020.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Saleh ZM, Bloom PP, Grzyb K, Tapper EB. How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study. Hepatol Commun 2021;5:168-76. [PMID: 33553967 DOI: 10.1002/hep4.1621] [Reference Citation Analysis]
89 Guerrero L, Sangro B, Ambao V, Granero JI, Ramos-Fernández A, Paradela A, Corrales FJ. Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease. J Physiol Biochem 2021. [PMID: 34897580 DOI: 10.1007/s13105-021-00856-3] [Reference Citation Analysis]